Chronic Lymphocytic Leukemia

Common Name(s)

Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes (a type of white blood cell) that begins in the stem cells of the bone marrow and then invades the blood. Overtime, CLL may also spread to the lymph nodes and other organs including the liver, spleen and lungs.  It occurs when the stem cells that make lymphocytes become out of control and produce increasing amounts of abnormal lymphocytes (also called leukemic cells). Eventually, these abnormal cells replace normal lymphocytes and can crowd out other types of normal blood cells, leading to the features of the condition. Early signs and symptoms of CLL may include fatigue, weight loss, loss of appetite, fever, night sweats and/or frequent infections.  The exact underlying cause of CLL is unknown; however, approximately 5% of affected people have other family members with the condition, which suggests there may be a genetic component in rare cases. The best treatment depends on many factors including the stage of the condition, the age of the affected person, the blood cell counts, whether the CLL has recurred, and the signs and symptoms present in each person.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Lymphocytic Leukemia" for support, advocacy or research.

4th Angel Mentoring Program

Learning that you have cancer can be an overwhelming experience – one that leaves you frightened, vulnerable and alone. The 4th Angel Mentoring Program offers free, one-on-one, confidential outreach and support from someone who has successfully made the same journey you are about to begin – the journey towards recovery. This specially trained volunteer and cancer survivor – your 4th Angel – is someone who will talk and listen in a supportive setting. The 4th Angel Mentoring Program is telephone based, so you can be connect with an angel anywhere in the country. 4th Angel Mentoring Program is part of The Scott Hamilton CARES Initiative, a national non-profit organizat

Last Updated: 12 Dec 2012

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Lymphocytic Leukemia" for support, advocacy or research.

4th Angel Mentoring Program

Learning that you have cancer can be an overwhelming experience – one that leaves you frightened, vulnerable and alone. The 4th Angel Mentoring Program offers free, one-on-one, confidential outreach and support from someone who has successfully made the same journey you are about to begin – the journey towards recovery. This specially trained volunteer and cancer survivor – your 4th Angel – is someone who will talk and listen in a supportive setting. The 4th Angel Mentoring Program is telephone based, so you can be connect with an angel anywhere in the country. 4th Angel Mentoring Program is part of The Scott Hamilton CARES Initiative, a national non-profit organizat

http://www.4thangel.org

Last Updated: 12 Dec 2012

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Lymphocytic Leukemia" returned 2591 free, full-text research articles on human participants. First 3 results:

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
 

Author(s): Susan M O'Brien, Nicole Lamanna, Thomas J Kipps, Ian Flinn, Andrew D Zelenetz, Jan A Burger, Michael Keating, Siddhartha Mitra, Leanne Holes, Albert S Yu, David M Johnson, Langdon L Miller, Yeonhee Kim, Roger D Dansey, Ronald L Dubowy, Steven E Coutre

Journal: Blood. 2015 Dec;126(25):2686-94.

 

Idelalisib is a first-in-class oral inhibitor of PI3Kδ that has shown substantial activity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as initial therapy, 64 treatment-naïve older patients with CLL or small lymphocytic leukemia ...

Last Updated: 18 Dec 2015

Go To URL
Temporal bone metastasis as a sign of relapsing chronic lymphocytic leukemia.
 

Author(s): Hadeel M Aljafar, Sari S Alsuhibani, Mohammad S Alahmari, Musaed A Alzahrani

Journal: Saudi Med J. 2015 Oct;36(10):1233-5.

 

Otologic manifestations in chronic lymphocytic leukemia (CLL) are common presentations. However, temporal bone metastasis is rarely described as a sign of relapsing CLL. A 65-year-old male diabetic patient known to have CLL on remission presented to the outpatient otolaryngology clinic ...

Last Updated: 8 Oct 2015

Go To URL
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.
 

Author(s): F Boissard, J-J Fournié, A Quillet-Mary, L Ysebaert, M Poupot

Journal:

 

Last Updated: 3 Oct 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Lymphocytic Leukemia" returned 187 free, full-text review articles on human participants. First 3 results:

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
 

Author(s): Klaus Okkenhaug, Jan A Burger

Journal: Curr. Top. Microbiol. Immunol.. 2016 ;393():123-42.

 

B cells provide immunity to extracellular pathogens by secreting a diverse repertoire of antibodies with high affinity and specificity for exposed antigens. The B cell receptor (BCR) is a transmembrane antibody, which facilitates the clonal selection of B cells producing secreted ...

Last Updated: 28 Dec 2015

Go To URL
Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.
 

Author(s): Kanti R Rai

Journal:

 

Chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, is primarily a disease of the elderly, with most patients ≥65 years of age and having at least one major comorbidity. Aggressive chemoimmunotherapy regimens recommended to achieve remission ...

Last Updated: 3 Aug 2015

Go To URL
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
 

Author(s): Karen Seiter, Aleksandra Mamorska-Dyga

Journal:

 

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Fludarabine-based regimens demonstrate higher response rates in younger patients but have a significant risk of infection and are thus poorly tolerated by older, frail patients. Anti-CD20 ...

Last Updated: 25 Jun 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
 

Status: Recruiting

Condition Summary: Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change

 

Last Updated: 26 May 2016

Go to URL
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
 

Status: Recruiting

Condition Summary: Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia

 

Last Updated: 10 Nov 2015

Go to URL
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
 

Status: Recruiting

Condition Summary: Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia

 

Last Updated: 18 Apr 2016

Go to URL